Intra-tumor heterogeneity for endometrial cancer and its clinical significance
Open Access
- 5 July 2019
- journal article
- research article
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 132 (13) , 1550-1562
Abstract
Management of tumors has become more complex owing to tumor heterogeneity. Fewer studies have been performed on intra-tumor heterogeneity of endometrial cancer (EC) until now. Therefore, it is of great clinical value to explore the intra-tumor heterogeneity of EC based on clinical features and gene expression profiles. A total of 1688 patients with EC were screened and 114 patients were finally selected, including specimens from 84 patients with primary EC without relapse (PE) and the paired metastases (P-M) specimens, as well as specimens from 30 patients with primary EC with relapse (RPE) and the paired relapsed EC (P-RE) specimens. Microarray and RNA-seq were used to detect gene expression of EC samples. Clinicopathological characteristics and molecular data were compared between PE and P-M groups and between RPE and P-RE groups to explore the intra-tumor heterogeneity of EC. The clinical intra-tumor spatial heterogeneity of pathological type, grade, ER status, and PR status between PE and P-M were 17.9%, 13.1%, 28.6%, and 28.6%, respectively. The clinical intra-tumor spatiotemporal heterogeneity of pathological type, grade, ER status, and PR status between RPE and P-RE were 16.7%, 33.3%, 25.0%, and 37.5%, respectively. Cluster analysis sorts EC samples based on progression type of lesion and their pathological type. There were differentially expressed genes between PE and P-M and between RPE and P-RE, of which gene ontology and Kyoto Encyclopedia of Genes and Genomes analysis were mainly enriched in cell proliferation, the p53 signaling pathway, etc. Clinical and molecular data showed that there was spatiotemporal heterogeneity in intra-tumor of EC, which may add to the complexity of diagnosis and therapeutics for EC. Considering the intra-tumor heterogeneity, sequential chemotherapy and precision medicine may be a more suitable treatment plan for EC. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0Keywords
This publication has 48 references indexed in Scilit:
- Integrated genomic characterization of endometrial carcinomaNature, 2013
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012
- Intratumor Heterogeneity in Evolutionary Models of Tumor ProgressionGenetics, 2011
- Endometrial Carcinoma: A Review of Chemotherapy, Drug Resistance, and the Search for New AgentsThe Oncologist, 2010
- Prognostic Value of E-Cadherin Expression and CDH1 Promoter Methylation in Patients With Endometrial CarcinomaCancer Investigation, 2010
- Resistance to chemotherapy and hormone therapy in endometrial cancerEndocrine-Related Cancer, 2009
- Common genetic variability in ESR1 and EGF in relation to endometrial cancer risk and survivalBritish Journal of Cancer, 2009
- FIGO Staging of Endometrial Adenocarcinoma: A Critical Review and ProposalInternational Journal of Gynecological Pathology, 2009
- Genetic clonal diversity predicts progression to esophageal adenocarcinomaNature Genetics, 2006
- Heterogeneity in hormone receptor status in primary and metastatic endometrial cancerGynecologic Oncology, 1990